This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Merck Patent Gmbh. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Innovations in Cancer Therapeutics by Andreas Machl
Introduction
Andreas Machl is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer therapeutics, focusing on innovative combinations of existing treatments. His work aims to enhance the efficacy of cancer therapies, providing hope for improved patient outcomes.
Latest Patents
Andreas Machl holds 1 patent related to his research. His patent, titled "Combinations of cancer therapeutics," involves the use of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, in conjunction with an inhibitor of Her2. This innovative combination is designed for the treatment of cancer, showcasing Machl's commitment to advancing medical science.
Career Highlights
Andreas Machl is associated with Merck Patent GmbH, where he continues to develop groundbreaking therapeutic solutions. His work at Merck has positioned him as a key player in the pharmaceutical industry, contributing to the development of effective cancer treatments.
Collaborations
Throughout his career, Machl has collaborated with esteemed colleagues, including Bayard R Huck and Erik W Wilker. These partnerships have fostered a collaborative environment that enhances the research and development of innovative cancer therapies.
Conclusion
Andreas Machl's contributions to cancer therapeutics through his innovative patent demonstrate his dedication to improving treatment options for patients. His work at Merck and collaborations with other experts in the field highlight the importance of teamwork in advancing medical research.